Glucose Regulation Beyond HbA1c in Type 2 Diabetes Treated With Insulin: Real-World Evidence From the DIALECT-2 Cohort

被引:9
|
作者
den Braber, Niala [1 ,2 ]
Vollenbroek-Hutten, Miriam M. R. [1 ,2 ]
Westerik, Kathryn M. [1 ]
Bakker, Stephan J. L. [3 ]
Navis, Gerjan [3 ]
van Beijnum, Bert-Jan F. [2 ]
Laverman, Gozewijn D. [1 ]
机构
[1] Ziekenhuisgrp Twente, Dept Internal Med, Div Nephrol, Twente, Netherlands
[2] Univ Twente, Biomed Signals & Syst, Enschede, Netherlands
[3] Univ Groningen, Univ Med Ctr Groningen, Dept Internal Med, Div Nephrol, Groningen, Netherlands
关键词
GLYCEMIC VARIABILITY; HYPOGLYCEMIA; INTERVENTION; CARE; IDDM;
D O I
10.2337/dc20-2241
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE To investigate glucose variations associated with glycated hemoglobin (HbA(1c)) in insulin-treated patients with type 2 diabetes. RESEARCH DESIGN AND METHODS Patients included in Diabetes and Lifestyle Cohort Twente (DIALECT)-2 (n = 79) were grouped into three HbA(1c) categories: low, intermediate, and high (<= 53, 54-62, and >= 63 mmol/mol or <= 7, 7.1-7.8, and >= 7.9%, respectively). Blood glucose time in range (TIR), time below range (TBR), time above range (TAR), glucose variability parameters, day and night duration, and frequency of TBR and TAR episodes were determined by continuous glucose monitoring (CGM) using the FreeStyle Libre sensor and compared between HbA(1c) categories. RESULTS CGM was performed for a median (interquartile range) of 10 (7-12) days/patient. TIR was not different for low and intermediate HbA(1c) categories (76.8% [68.3-88.2] vs. 76.0% [72.5.0-80.1]), whereas in the low category, TBR was higher and TAR lower (7.7% [2.4-19.1] vs. 0.7% [0.3-6.1] and 8.2% [5.7-17.6] vs. 20.4% [11.6-27.0], respectively; P < 0.05). Patients in the highest HbA(1c) category had lower TIR (52.7% [40.9-67.3]) and higher TAR (44.1% [27.8-57.0]) than the other HbA(1c) categories (P < 0.05), but did not have less TBR during the night. All patients had more (0.06 +/- 0.06/h vs. 0.03 +/- 0.03/h; P = 0.002) and longer (88.0 [45.0-195.5] vs. 53.4 [34.4-82.8] minutes; P < 0.001) TBR episodes during the night than during the day. CONCLUSIONS In this study, a high HbA(1c) did not reduce the occurrence of nocturnal hypoglycemia, and low HbA(1c) was not associated with the highest TIR. Optimal personalization of glycemic control requires the use of newer tools, including CGM-derived parameters.
引用
收藏
页码:2238 / 2244
页数:7
相关论文
共 50 条
  • [1] The Contribution of Postprandial Glucose Levels to Hyperglycemia in Type 2 Diabetes Calculated from Continuous Glucose Monitoring Data: Real World Evidence from the DIALECT-2 Cohort
    den Braber, Niala
    Vollenbroek-Hutten, Miriam M. R.
    Teunissen, Sacha E. M.
    Oosterwijk, Milou M.
    Kappert, Kilian D. R.
    Laverman, Gozewijn D.
    NUTRIENTS, 2024, 16 (20)
  • [2] Interactions between early DPP-4is initiation and HbA1c variability with risk of insulin requirement in type 2 diabetes: real-world evidence from a prospective cohort
    Yang, A.
    Cheung, J.
    Wu, H.
    Lau, E. S.
    Ma, R. C.
    Kong, A. P.
    So, W. Y.
    Luk, A. O.
    Chan, J. C.
    Chow, E.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S319 - S319
  • [3] Efficacy of flash glucose monitoring on HbA1c in type 2 diabetes: An individual patient data meta-analysis of real-world evidence
    Heer, Randeep S.
    Lovegrove, Joshua
    Welsh, Zoe
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2025, 219
  • [4] Impact of continuous glucose monitoring use on glycated haemoglobin (HbA1c) in people with type 2 diabetes: real-world analysis
    Bergenstal, R. M.
    Hirsch, I. B.
    Repetto, E.
    Snell-Bergeon, J.
    Ulmer, B.
    Perkins, C.
    Garg, S. K.
    DIABETOLOGIA, 2024, 67 : S103 - S103
  • [5] Clinical benefit of simultaneous initiation of basal insulin and GLP-1 in patients with type 2 diabetes and elevated HbA1c as supported by real-world evidence
    Guerci, B.
    Raccah, D.
    Lew, E.
    Meyers, J.
    Shaunik, A.
    Ajmera, M.
    Davis, K. L.
    Blonde, L.
    DIABETOLOGIA, 2017, 60 : S310 - S310
  • [6] HbA1c Is an Insufficient Glucose Control Assessment Tool in Type 1 and Type 2 Treated with Insulin
    Totomirova, Tzvetelina
    Arnaudova, Mila
    Daskalova, Ivona
    DIABETES, 2020, 69
  • [7] Relationship between Baseline HbA1c, Change in HbA1c, and Clinical Outcomes in Type 2 Diabetes: A Comparison of Clinical Guidelines and Real-World Data
    Mcewan, Phil
    Gordon, Jason P.
    Evans, Marc
    Viana, Ricardo
    Paldanius, Paivi M.
    DIABETES, 2016, 65 : A575 - A575
  • [8] The Diabetes Unmet Need with Basal Insulin Evaluation (DUNE) study in type 2 diabetes: Achieving HbA1c targets with basal insulin in a real-world setting
    Meneghini, Luigi F.
    Mauricio, Didac
    Orsi, Emanuela
    Lalic, Nebojsa M.
    Cali, Anna M. G.
    Westerbacka, Jukka
    Stella, Peter
    Candelas, Christophe
    Pilorget, Valerie
    Perfetti, Riccardo
    Khunti, Kamlesh
    DIABETES OBESITY & METABOLISM, 2019, 21 (06): : 1429 - 1436
  • [9] Use of flash glucose monitoring is associated with HbA1c reduction in type 2 diabetes managed with basal insulin in Canada: A real-world prospective observational study
    Abitbol, Alexander
    Jain, Akshay B.
    Tsoukas, Michael A.
    Sigalas, John
    Galm, Brandon P.
    Lee, Jooho
    Qureshy, Kamran S.
    Collins, Caitlyn
    Woo, Vincent C.
    DIABETES & VASCULAR DISEASE RESEARCH, 2024, 21 (03):
  • [10] Distinct HbA1c trajectories in a type 2 diabetes cohort
    Walraven, Iris
    Mast, M. Ruth
    Hoekstra, Trynke
    Jansen, A. P. Danielle
    van der Heijden, Amber A. W. A.
    Rauh, Simone P.
    Rutters, Femke
    van't Riet, Esther
    Elders, Petra J. M.
    Moll, Annette C.
    Polak, Bettine C. P.
    Dekker, Jacqueline M.
    Nijpels, Giel
    ACTA DIABETOLOGICA, 2015, 52 (02) : 267 - 275